

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
8 June 2006 (08.06.2006)

PCT

(10) International Publication Number  
WO 2006/059328 A1(51) International Patent Classification:  
*A61P 29/00* (2006.01)(74) Agent: REINHOLD COHN AND PARTNERS; P.O.  
Box 4060, 61040 Tel Aviv (IL).(21) International Application Number:  
PCT/IL2005/001280

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:  
30 November 2005 (30.11.2005)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:  
60/632,198 2 December 2004 (02.12.2004) US  
60/657,718 3 March 2005 (03.03.2005) US(71) Applicant (for all designated States except US):  
**CAN-FITE BIOPHARMA LTD.** [IL/IL]; 10 Bareket Street, P.O. Box 7537, 49170 Petach Tikva (IL).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **FISHMAN, Pnina** [IL/IL]; 19 Asher Barash Street, 46365 Herzliya (IL). **BAR-YEHUDA, Sara** [IL/IL]; 21B Arbel Street, 75474 Rishon Le Zion (IL).*[Continued on next page]*

(54) Title: TREATMENT OF INFLAMMATION



A



(57) Abstract: The present invention concerns the therapeutic treatment of inflammatory conditions by a combined administration of methotrexate and an agonist of the A3 adenosine receptor. Provided are methods of therapeutic treatment comprising such a combined administration, pharmaceutical compositions useful in such methods comprising either an and use if either an agonist of the A3 adenosine receptor or methotrexate, as well as used of any of these active agents for preparing such a pharmaceutical composition.

WO 2006/059328 A1



**Published:**

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*